Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

22.500
-0.500-2.17%
Volume:1.06M
Turnover:23.62M
Market Cap:19.62B
PE:43.27
High:22.960
Open:22.960
Low:22.200
Close:23.000
52wk High:26.000
52wk Low:15.570
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:0.19
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.520
ROE:1.46%
ROA:-1.24%
PB:1.98
PE(LYR):43.27
PS:4.55

Loading ...

Hutchmed (China) - Agreement Includes $110 Mln Upfront, up to $1.30 Bln in Milestones, Plus Royalties

THOMSON REUTERS
·
Sep 03

Hutchmed Announces Licensing Agreement with GSK for Kras-Egfr-Antibody Conjugate Cancer Therapy

THOMSON REUTERS
·
Sep 03

Hong Kong Stocks Edge Lower on Monday Amid Middle East Tensions; HUTCHMED Falls 2%

MT Newswires Live
·
Aug 31

Hutchmed Says Savolitinib Plus AstraZeneca’s Tagrisso Extends PFS in China Phase III Sanovo Lung Cancer Trial

Reuters
·
Aug 31

HUTCHMED Sees Positive High Level Results in Lung Cancer Drug Combo Trial

MT Newswires Live
·
Aug 31

Hutchmed (China) - Announces Positive Results from Sanovo China Phase Trial in Nsclc Patients

THOMSON REUTERS
·
Aug 31

Hutchmed Announces Sanovo Trial Demonstrated Significant Progression-Free Survival Benefit of Orpathys® Plus Tagrisso® in Treatment-NaÏVe Patients with Met-Overexpressing Egfr-Mutated Lung Cancer in China

THOMSON REUTERS
·
Aug 31

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires Live
·
Aug 28

Hutchmed (China) Announces NMPA Conditional Approval for ATLED in China

Reuters
·
Aug 28

HUTCHMED's Cholangiocarcinoma Drug Application Gets Conditional Nod in China

MT Newswires Live
·
Aug 28

Hutchmed (China) - Fanregratinib to be Marketed in China as Atled

THOMSON REUTERS
·
Aug 28

Hong Kong Market Movers: Mixue's Revenue Reaches RMB 15.2 Billion in First Half, Global Store Network Expands

Stock News
·
Aug 28

HUTCHMED Secures NMPA Conditional Approval for ATLED® (Fanregratinib) Targeting FGFR2-Altered Intrahepatic Cholangiocarcinoma

Bulletin Express
·
Aug 28

HUTCHMED secures NMPA approval for ATLED to address FGFR2-altered intrahepatic cholangiocarcinoma

Stock News
·
Aug 28

Hutchmed (China) - Announces Nmpa Conditional Approval for Atled (Fantegratinib) in China

THOMSON REUTERS
·
Aug 28

Hutchmed Says China NMPA Approves ATLED for FGFR2-Altered Intrahepatic Cholangiocarcinoma

Reuters
·
Aug 28

Hutchmed Announces Nmpa Approval for Atled® (Fanregratinib) for the Treatment of Patients with Fgfr2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

THOMSON REUTERS
·
Aug 28

Dow Jones Top Company Headlines at 1 PM ET: Walmart Shares Slump on Weakest Sales Growth in over Six Years | Super ...

Dow Jones
·
Aug 21

Dow Jones Top Company Headlines at 7 am ET: Alibaba Posts Weaker Earnings Amid Heavy AI Investments | Deere's ...

Dow Jones
·
Aug 20

Hutchmed (China) Ltd: Insolvency Proceedings Remain Ongoing, Outcome of Proceedings is not Known to Company as at Date of This Announcement

THOMSON REUTERS
·
Aug 18